Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. - Dapagliflozin resulted in decreased cardiovascular mortality and hospitalizations due to heart failure while improving patient-reported health status in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), researchers herein estimated whether dapagliflozin therapy is cost-effective among patients suffering from chronic heart failure with reduced ejection fraction. From the DAPA-HF trial and other published literature, estimates of therapy effectiveness, transition probabilities, and utilities were used. In the model, a mean of 0.78 additional life-years and 0.46 additional quality-adjusted life-years (QALYs) were offered by dapagliflozin therapy, vs standard of care (SOC), at an incremental expense of $38,212, resulting in a cost per QALY gained of $83 650. On the basis of American College of Cardiology/American Heart Association benchmarks, intermediate value is offered by dapagliflozin vs SOC, as indicated by the findings of this study. Additional data concerning the magnitude of mortality attenuation would improve the precision of cost-effectiveness estimates.